Methods: from the medical literature a compilation of the results of adjuvant treatment of gastric cancer were reviewed and critically analyzed. Asurgicalrationale for integrating intraperitoneal chemotherapy into the management of advanced primary gastric cancer was sought.
neal carcinomatosis occurred in amajority of patients who failed the surgical treatment of primary gastric cancer.T hese authors suggested an ovel treatment, early postoperative intraperitoneal chemotherapy with 5-fluorouracil, doxorubicin, and/or cisplatin.
The pharmacologic rationale for this direct instillation of chemotherapy into the peritoneal cavity after ap otentially curative gastrointestinal cancer resection was further developedb yS ugarbaker and colleagues using pharmacologic studies (2).Highl ocal-regional concentrations of intraperitoneal chemotherapy,p rolonged exposureo ft he peritoneal surfaces, and aminimum of systemic toxicity was demonstrated. 5-fluorouracil was thought to protect not only the peritoneal surfaces but also act as an adju-
INTroDUCTIoN
The rationale for adding perioperative chemotherapy to the management of gastrointestinal and ovarian cancer was developedbyCunliffe and Sugarbaker in 1989. They based the rationale for this novel approach on the patterns of recurrence of both gastrointestinal and ovarian cancer (1). Their literaturereview established that the resection site recurrence and perito-vant to prevent the development of liver metastases. Mitomycin C wassuggested as a chemotherapy agent with awide range of responses in both gastrointestinal and gynecologic malignancy that was pharmacologically appropriate for perioperative intraperitoneal administration.
The addition of heat to the intraperitoneal chemotherapy treatments was first explored by Spratt et al (3) . They treated as ingle patient with pseudomyxoma peritonei and established that both heat and chemotherapy werew ell tolerated in this patient and promised to develop into an effective treatment strategy for patients with the dissemination of cancer on peritoneal surfaces. Koja and colleagues performed pharmacologic studies withh eated intraperitoneal chemotherapyi ne xperimental animals and then went on to perform an early trial in patients with primary gastric cancer to test the efficacy of heated intraoperative intraperitoneal chemotherapy in patients with resected gastric cancer (4, 5).
Gastric cancer may be the gastrointestinal cancer thatcan be most effectively treated by adjuvant intraperitoneal chemotherapy with significant benefit. Sugarbaker summarized the surgical approach that would incorporate peritonectomy into the management of gastric cancer with peritoneals eeding. He also developed the concept of centripetal gastrectomy which would minimize the contamination of the resection siteb yc ancer cells traumatically disrupted from the primary tumor as ar esult of the cancer resection (6).
In 1988 Koja and colleagues from Tottori University,Y onago, Japan publishedp romising results in a historically controlled study of 38 patients and in a randomized controlled study of 47 patients (5). Their results showedastatistically significant improvement in survival in the historical control group (p =0.04).
In the randomized study,c onsidered to be grossly statisticallyu nderpowered, therew as no significant improvement in survival. However,itshould be mentioned that the 3-year survival of the treated group was 83% as compared to 67% in those patients who had gastrectomy alone. The incidence of anastomotic leak in the two groups of patients was similar.T his group is to be credited with providing us with the first promising results from adjuvant treatmento f gastric cancer with perioperative intraperitoneal chemotherapy.
Fujimuraa nd colleagues from Kanazawa University,Kanazawa, Japan used cisplatin and mitomycin Cinarandomized controlled study of hyperthermic and normothermic intraoperative chemotherapy (7). The group receiving heated intraoperative intraperitoneal chemotherapy had a68% 3-year survival, the groupr eceiving normothermic intraperitoneal chemotherapy had a51% 3-year survival, and the group havings urgery alone had a2 3% 3-year survival. These three curves weresignificantly different by the Log-ranktest (p <0.01). The Kanazawa group should be creditedw ith as ound pharmacologic study of their patients,w ith data that strongly suggested the benefits of hyperthermia and with the provision of data that further supports the perioperative use of intraperitoneal chemotherapy for gastric cancer.
Hamazoeand coworkers in 1993 from Tottori University in Yonago, Japan published ar andomized controlled study of hyperthermic peritoneal irrigation with mitomycin C( 8). Forty-two patients were in the experimental arm and 40 patients had gastrectomy only.The 5-year survival rate was 64.2% for the treated patients and 52.5% for the control group. This was statistically insignificant with ap-value of 0.243. However,t he mortality ratef romp eritoneal recurrence was less in the treated group and this result approached statistical significance (p =0.085).
Yonemura and colleagues in 1995 published asecond study of 79 patients who had the prophylactic treatmentfor peritoneal recurrence with heated intraoperative intraperitoneal chemotherapyu sing mitomycin Ca nd cisplatin as compared to 81 patients who underwent potentially curative surgery during the same period (9). These important data showed that therew as no difference in survival in patients with histologically-proven, serosal invasion-negative tumors.However,iftherewas histologically-proven serosal invasion by tumor,t herew as a5 -year survival of 50% in the treated group as compared to 30% in the control. This was statistically significant with ap -value of 0.016. Also, surprisingly those patients with stage IV disease showed a4 5% survival with heated intraperitoneal chemotherapy treatment as compared to 5% at 5years in the control group. This was statistically significant with ap -value <0 .001. Yonemura and colleagues suggested that hyperthermic intraperitonealirrigation intraoperatively was an important adjunct to the treatment of patients with serosal invasion-positive gastric cancer.
Ikeguchi and colleagues in 1995 reported on 174 randomizedp atients treated with gastrectomy plus heated intraperitoneal chemotherapy versus gastrectomy and standard systemicc hemotherapy (10) In the group of patients with 1-9 lymph node metastases therewas atrend towards increased 5-year survival. Sixty-six percent in the treated group survived 5years as compared to 44% in the control group (p =0.084). In the group with no lymph nodes positive or patients with 10 or more lymph nodes positive, the beneficial effects of heated intraperitoneal chemotherapy weren ot evident. These authors noted that the incidence of free cancer cells in the peritoneal cavity was 6% in patients without positivelymph nodes,17% in patients with 1-9 positive lymph nodes, and 38% in Patients with gastric cancerrecommended for perioperative intraperitoneal chemotherapy.
Positive peritoneal cytology ovarian involvement Peritoneal seeding on the serosal surface of the stomach ruptureofanecrotic tumor mass Adjacent organ involvement Intraoperative tumor spill Perforation of the primary tumor Involved lymph nodes at the margin of excision Limited peritoneal seeding with aperitoneal cancer index of <20 Limited peritoneal seeding so that acomplete cytoreduction can be achieved patients with 10 or morep ositive nodes. These authors suggest that patientswith lymph node positivity should be expected to have ah igh rate of localregional recurrence and peritoneal metastases in the absence of alocal-regional adjuvant treatment. Fujimoto and colleagues in 1999 from Funabashi, Japan, treated 141 gastric cancer patients with macroscopic serosal invasion and randomly assignedthese patients to two groups (11) . Seventy-one patients underwent hyperthermic intraoperative intraperitoneal chemotherapy and the other group underwent gastric resection alone. The peritoneal recurrence rate in the treated group was significantly decreased (p ≤0.0001). The 8-year survival in the treated group was 62% and 49% in the control group. This was asignificant benefit with ap -value of 0.036. This group concluded that heated intraoperative intraperitoneal chemotherapy reduced the local recurrence rate and improved the long-termsurvival in patients with gastric cancer who had macroscopic serosal invasion.
Yu and colleagues from Kyungpook University, Taegu, Korea, published ar andomized controlled study of 248 patients with advanced gastric cancer. These patients weretreated with early postoperative intraperitoneal chemotherapy usingm itomycin C and 5-fluorouracil in addition to gastrectomy or gastrectomya lone. The 5-year survival rate in patients with stage III disease was 18% for the surgery only group and 49% in the group that had surgery plus intraperitoneal chemotherapy (p =0.11) (12) . In afollow-up of these data three years later the overall survival was improved in the treated group with a5year overall survival of 54% in the treated group and 38% in the gastrectomy only group (p =0.0278). The patients who profited most werethose who had gross serosal invasion (13) . In this group the survival was 52% in the treated group and 25% in the gastrectomy alone group (p <0.0001). In patients with resectable stage IV cancer the survival was 28% in the treated group and 5% in the gastrectomyo nly group (p =0.0098).
The morbidity and mortality of the early postoperative intraperitoneal chemotherapy was addressed by Yu and colleagues in further publications (14) . The overall morbidity was higher in the control group, 28.8% versus 20%. This difference was not significant. Intra-abdominal sepsis without anastomotic leak (p =0.008) and postoperative bleeding (p =0.002) occurred moreoften in the study group. Postoperative mortality was higher in the study group (5.6%) than in the control( 0.8%) but this was not significant (p =0.299). Yu and colleagues performed ap eriod analysis of the morbidity demonstrating that it followed apattern of alearning curve.
recently,am eta-analysis of adjuvant intraperitoneal chemotherapy for gastric cancer was reported by Xu andc olleagues from Sun Yat-senU niversity in Guangzhou, China (15) . They pooledt he data from 11 trials involving 1161 cases. Their conclusion was that intraperitoneal chemotherapy benefits patients after ac urative resection. The odds ratio was 0.51 with a9 5% confidence interval of 0.40-0.65. Xu and colleagues suggested that intraperitoneal chemotherapy was of benefit but indicated that rigorously de-signed trialss hould be conducted to draw mored efinitive conclusions.
Asingle study in the adjuvant treatment of gastric cancer is important in that it shows an absence of benefit. The multi-institutional studyr eported by Sautner and colleagues from Austria used multiple cycles of delayed intraperitoneal cisplatin as an adjuvant to gastric cancer resection (16) . This failed to show any benefit. This is understandablew hen one looks into the mechanism of action of early postoperative intraperitoneal chemotherapy in an adjuvant setting. It is used to prevent local-regionald isease dissemination that occurs prior to or at the time of surgery.I ti sm orel ikely to occur in patients who have serosal-positive disease or lymph node positivity.Starting the chemotherapy amonth after surgery from this perspective is unlikely to be of any benefit. As expected no benefitwas observed in this study.
recently,S ugarbaker reviewed all of the agents that have been suggested for intraperitoneal chemotherapy delivery (17) . He suggested that some agents arei deal for use withint he peritoneal cavity.L arge chemotherapy molecules arecleared slowly from the peritoneal space and provide excellent prophylaxis against microscopic residual disease. othera gents areofless benefit intraperitoneally and may interfere with long-term intraperitoneal access by causing a sclerotic reaction and the resulting non-uniform drug delivery to peritoneal surfaces.
CoNCLUSIoN
The natural history studies suggest that local-regional recurrence of gastricc ancer is an important part of surgical treatment failure. Also, the pharmacology of intraperitoneal chemotherapy suggests that it should be abletoeradicate microscopic residual disease and av ery low volume of carcinomatosis. Phase II and phase III studies and ar ecent meta-analysis suggest that intraperitoneal chemotherapy is of benefit in resectable gastric cancer.Itappears to have its greatest benefit in patients who have invasion of the serosa. Also, in resectable stage IV gastric cancer patients, when the surgery is radical, survival is benefited by this approach. The timing of this intraperitoneal chemotherapy must be perioperative as ap lanned part of the operative intervention. Ab idirectional approach chemotherapy administrationboth perioperatively and long-termwill likely result in the greatest improvement in survival. Knowledgeable selection of drugs for intraperitoneal administration to treat local-regionaldisease combined with intravenous chemotherapy to help control systemic microscopic disease is recommended. rEFErENCES 0 1. Cunliffe WJ, Sugarbaker PH: Gastrointestinal malignancy: rationale for adjuvant therapy using early postoperative intraperitoneal chemotherapy (EPIC). br JSurg1989;76:1082-1090 0 2. Sugarbaker PH, Graves T, Debruijn EA, Cunliffe WJ, Mullins rE, Hull WE, oliffL,Schlag P: rationalefor early postoperative
